These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
420 related articles for article (PubMed ID: 35096487)
1. Identification of a unique tumor cell subset employing myeloid transcriptional circuits to create an immunomodulatory microenvironment in glioblastoma. Yang K; Shi Y; Luo M; Mao M; Zhang X; Chen C; Liu Y; He Z; Liu Q; Wang W; Luo C; Yin W; Wang C; Niu Q; Zeng H; Bian XW; Ping YF Oncoimmunology; 2022; 11(1):2030020. PubMed ID: 35096487 [TBL] [Abstract][Full Text] [Related]
2. Immune Microenvironment in Glioblastoma Subtypes. Chen Z; Hambardzumyan D Front Immunol; 2018; 9():1004. PubMed ID: 29867979 [TBL] [Abstract][Full Text] [Related]
3. Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment. Jeanmougin M; Håvik AB; Cekaite L; Brandal P; Sveen A; Meling TR; Ågesen TH; Scheie D; Heim S; Lothe RA; Lind GE Mol Oncol; 2020 May; 14(5):1016-1027. PubMed ID: 32171051 [TBL] [Abstract][Full Text] [Related]
4. Combining single-cell sequencing and spatial transcriptome sequencing to identify exosome-related features of glioblastoma and constructing a prognostic model to identify BARD1 as a potential therapeutic target for GBM patients. Zhao S; Wang Q; Ni K; Zhang P; Liu Y; Xie J; Ji W; Cheng C; Zhou Q Front Immunol; 2023; 14():1263329. PubMed ID: 37727789 [TBL] [Abstract][Full Text] [Related]
5. Single-cell RNA sequencing reveals tumor heterogeneity, microenvironment, and drug-resistance mechanisms of recurrent glioblastoma. Wu H; Guo C; Wang C; Xu J; Zheng S; Duan J; Li Y; Bai H; Xu Q; Ning F; Wang F; Yang Q Cancer Sci; 2023 Jun; 114(6):2609-2621. PubMed ID: 36853018 [TBL] [Abstract][Full Text] [Related]
6. Construction of Interferon-Gamma-Related Gene Signature to Characterize the Immune-Inflamed Phenotype of Glioblastoma and Predict Prognosis, Efficacy of Immunotherapy and Radiotherapy. Ji H; Ba Y; Ma S; Hou K; Mi S; Gao X; Jin J; Gong Q; Liu T; Wang F; Liu Z; Li S; Du J; Hu S Front Immunol; 2021; 12():729359. PubMed ID: 34566988 [TBL] [Abstract][Full Text] [Related]
7. Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development. Lin H; Wang K; Xiong Y; Zhou L; Yang Y; Chen S; Xu P; Zhou Y; Mao R; Lv G; Wang P; Zhou D Front Immunol; 2022; 13():773264. PubMed ID: 35185876 [TBL] [Abstract][Full Text] [Related]
8. BACH1 as a potential target for immunotherapy in glioblastomas. Yuan F; Cong Z; Cai X; Zhu J; Yuan L; Wang Y; Tang C; Ma C Int Immunopharmacol; 2022 Feb; 103():108451. PubMed ID: 34923423 [TBL] [Abstract][Full Text] [Related]
9. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma. Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of caveolin-1 restores myeloid cell function in human glioblastoma. Shimato S; Anderson LM; Asslaber M; Bruce JN; Canoll P; Anderson DE; Anderson RC PLoS One; 2013; 8(10):e77397. PubMed ID: 24130882 [TBL] [Abstract][Full Text] [Related]
11. A novel Foxp3-related immune prognostic signature for glioblastoma multiforme based on immunogenomic profiling. Guo XY; Zhang GH; Wang ZN; Duan H; Xie T; Liang L; Cui R; Hu HR; Wu Y; Dong JJ; He ZQ; Mou YG Aging (Albany NY); 2021 Jan; 13(3):3501-3517. PubMed ID: 33429364 [TBL] [Abstract][Full Text] [Related]
12. Identification of T-cell exhaustion-related gene signature for predicting prognosis in glioblastoma multiforme. Liu YH; Jin HQ; Liu HP J Cell Mol Med; 2023 Nov; 27(22):3503-3513. PubMed ID: 37635346 [TBL] [Abstract][Full Text] [Related]
13. New insights for precision treatment of glioblastoma from analysis of single-cell lncRNA expression. Meng Q; Zhang Y; Li G; Li Y; Xie H; Chen X J Cancer Res Clin Oncol; 2021 Jul; 147(7):1881-1895. PubMed ID: 33693962 [TBL] [Abstract][Full Text] [Related]
14. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients. Wang Z; Wang Y; Yang T; Xing H; Wang Y; Gao L; Guo X; Xing B; Wang Y; Ma W Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33839757 [TBL] [Abstract][Full Text] [Related]
15. The N Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G Front Immunol; 2021; 12():653711. PubMed ID: 34354698 [TBL] [Abstract][Full Text] [Related]
16. Single-cell RNA sequencing reveals intra-tumoral heterogeneity of glioblastoma and a pro-tumor subset of tumor-associated macrophages characterized by EZH2 overexpression. Chen X; Chen Y; Chen X; Wei P; Lin Y; Wu Z; Lin Z; Kang D; Ding C Biochim Biophys Acta Mol Basis Dis; 2022 Dec; 1868(12):166534. PubMed ID: 36057370 [TBL] [Abstract][Full Text] [Related]
17. Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma. DeCordova S; Shastri A; Tsolaki AG; Yasmin H; Klein L; Singh SK; Kishore U Front Immunol; 2020; 11():1402. PubMed ID: 32765498 [TBL] [Abstract][Full Text] [Related]
18. Identification of Immune-Related lncRNA Prognostic Signature and Molecular Subtypes for Glioblastoma. Yu W; Ma Y; Hou W; Wang F; Cheng W; Qiu F; Wu P; Zhang G Front Immunol; 2021; 12():706936. PubMed ID: 34899682 [TBL] [Abstract][Full Text] [Related]
19. Antioxidant network-based signatures cluster glioblastoma into distinct redox-resistant phenotypes. Yang Y; More S; De Smet F; De Vleeschouwer S; Agostinis P Front Immunol; 2024; 15():1342977. PubMed ID: 38698847 [TBL] [Abstract][Full Text] [Related]
20. Glioblastoma-instructed microglia transition to heterogeneous phenotypic states with phagocytic and dendritic cell-like features in patient tumors and patient-derived orthotopic xenografts. Yabo YA; Moreno-Sanchez PM; Pires-Afonso Y; Kaoma T; Nosirov B; Scafidi A; Ermini L; Lipsa A; Oudin A; Kyriakis D; Grzyb K; Poovathingal SK; Poli A; Muller A; Toth R; Klink B; Berchem G; Berthold C; Hertel F; Mittelbronn M; Heiland DH; Skupin A; Nazarov PV; Niclou SP; Michelucci A; Golebiewska A Genome Med; 2024 Apr; 16(1):51. PubMed ID: 38566128 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]